Advertisement

#Bavencio

Bavencio

FDA Approves Bavencio for Bladder Carcinoma Maintenance Treatment

The immunotherapy is now approved for people whose cancer has not progressed on platinum-based chemotherapy.

Bavencio Plus Inlyta Gets Green Light for Kidney Cancer

FDA approves immunotherapy plus targeted therapy combo for initial treatment of advanced renal cell carcinoma.

Lori Wood, MD

Checkpoint Combos Improve Advanced Kidney Cancer Outcomes

Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.

Checkpoint Immunotherapy Combos Reduce Kidney Cancer Progression

Bavencio or Keytruda plus targeted therapy slowed disease progression in Phase III studies.

James Allison, PhD, Tasuku Honjo, MD, PhD

Cancer Immunotherapy Researchers Win Nobel Prize

James Allison and Tasuku Honjo recognized for immune checkpoint discoveries.

Red blood cells

Immunotherapy

Antibodies

Researchers Find New Immune Checkpoint—and a Drug to Block It

The experimental antibody BAY1905254 targets the newly discovered checkpoint ILDR2.

White blood cells

ASCO and NCCN Issue Guidelines on Managing Immunotherapy Side Effects

Taking the brakes off the immune system can lead to excessive responses that harm healthy organs and tissue.

Advertisement